Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-064699
Filing Date
2024-05-24
Accepted
2024-05-24 17:00:10
Documents
1
Period of Report
2024-05-22

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 5418
  Complete submission text file 0000950170-24-064699.txt   7986
Mailing Address 55 CAMBRIDGE PARKWAY 8TH FLOOR CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY 8TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Pioneering Fund VII, L.P. (Reporting) CIK: 0001805916 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39634 | Film No.: 24985319

Mailing Address 55 CAMBRIDGE PARKWAY 8TH FLOOR CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY 8TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Pioneering Fund VII General Partner LLC (Reporting) CIK: 0001805917 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39634 | Film No.: 24985320

Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Issuer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)